Page last updated: 2024-08-21

amiloride and sorafenib

amiloride has been researched along with sorafenib in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Mihaila, RG1
Chang, CS; Chang, JG; Chang, WH; Chang, YS; Chen, YC; Chen, YT; Hsu, KC; Lee, CC; Lin, SY; Liu, TY; Wu, YC; Yang, JM1
Kinoshita, Y; Matsuda, Y; Osawa, M; Wakai, T1

Reviews

2 review(s) available for amiloride and sorafenib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015, Volume: 159, Issue:4

    Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation

2015

Other Studies

3 other study(ies) available for amiloride and sorafenib

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide.
    Molecular oncology, 2019, Volume: 13, Issue:8

    Topics: Alternative Splicing; Amiloride; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase; Gene Expression Regulation, Neoplastic; Genome, Human; Heterogeneous-Nuclear Ribonucleoproteins; Histones; Humans; Mice, Inbred BALB C; Mitosis; Models, Molecular; Molecular Targeted Therapy; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Serine-Arginine Splicing Factors; Sorafenib; Xenograft Model Antitumor Assays

2019
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
    Anticancer research, 2021, Volume: 41, Issue:2

    Topics: Amiloride; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Sorafenib; Xenograft Model Antitumor Assays

2021